Post-Translational Modification of GPX4 is a Promising Target for Treating Ferroptosis-Related Diseases

Can Cui1, Fei Yang2,3 and Qian Li2,4,5*

1School of Basic Medical Sciences, Capital Medical University, Beijing, China, 2Advanced Innovation Center for Human Brain Protection, Beijing Key Laboratory of Neural Regeneration and Repair, Capital Medical University, Beijing, China, 3Department of Neurobiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China, 4Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Capital Medical University, Beijing, China, 5Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Capital Medical University, Beijing, China

Glutathione peroxidase 4 (GPX4) is one of the most important antioxidant enzymes. As the key regulator of ferroptosis, GPX4 has attracted considerable attention in the fields of cancer, cardiovascular, and neuroscience research in the past 10 years. How to regulate GPX4 activity has become a hot topic nowadays. GPX4 protein level is regulated transcriptionally by transcription factor SP2 or Nrf2. GPX4 activity can be upregulated by supplementing intracellular selenium or glutathione, and also be inhibited by ferroptosis inducers such as ML162 and RSL3. These regulatory mechanisms of GPX4 level/activity have already shown a great potential for treating ferroptosis-related diseases in preclinical studies, especially in cancer cells. Until recently, research show that GPX4 can undergo post-translational modifications (PTMs), such as ubiquitination, succination, phosphorylation, and glycosylation. PTMs of GPX4 affect the protein level/activity of GPX4, indicating that modifying these processes can be a potential therapy for treating ferroptosis-related diseases. This article summarizes the protein characteristics, enzyme properties, and PTMs of GPX4. It also provides a hypothetical idea for treating ferroptosis-related diseases by targeting the PTMs of GPX4.

Keywords: ferroptosis, post-translational modifications, cancer, enzyme, GPX4

INTRODUCTION

In 1982, a new glutathione peroxidase was first isolated from the pig liver (Ursini et al., 1982). Unlike previously discovered glutathione peroxidase 1-3 (GPX1-3), this new enzyme, phospholipid hydroperoxide glutathione peroxidase (PHGPX), acts directly on peroxidized phospholipids in the membrane. GPX1-3 are tetramers that mainly reduce H₂O₂ and fatty acid hydroperoxide (Gladyshev and Hatfield, 1999; Olson et al., 2010), whereas PHGPX is a monomeric protein and reduces lipid hydroperoxides specifically (Schuckelt et al., 1991). Later, PHGPX was renamed glutathione peroxidase 4 (GPX4) (Nam et al., 1998). Until 2014, GPX4 was identified as the central regulator of ferroptosis, which is an iron-dependent, non-apoptotic, programmed necroptotic cell death form (Dixon et al., 2012). How to regulate the protein level of GPX4 and its activity has become a hot topic to discover the potential treatment of ferroptosis-related diseases recently.
ENZYME PROPERTIES OF GPX4 AND ITS ROLE IN CANCER THERAPIES

The selenoprotein GPX4 has high antioxidant activity. It directly reduces phospholipid hydroperoxide through a conserved catalytic triad of selenocysteine 46, asparagine 81, and tryptophane 136 (Maiorino et al., 1995). The reaction kinetics of GPX4 is described as a Ping-Pong pattern that is embodied in two phases (Takebe et al., 2002) (Figure 1). Firstly, the peroxide is reduced through the active site selenocysteine 46 and then converted to the oxidized form (selenenic acid derivative). The second stage is to recharge the oxidized catalytic site via glutathione (GSH) (Takebe et al., 2002). The content of GSH and nicotinamide adenine dinucleotide phosphate (NADPH) directly affect the GPX4 activity.

Cystine/glutamate transporter (system $\chi_{C^{-}}$) on the cell membrane, composed of a catalytic subunit SLC7A11 and a chaperone subunit SLC3A2, pumps cystine from extracellular into cells for GSH biosynthesis (Bannai, 1986; Sato et al., 1999). Therefore, classic ferroptosis inducers (FINs) are divided into two classes (Figure 1): class I FIN such as sorafenib (Louandre et al., 2013), sulfasalazine (Gout et al., 2001), erastin (Dixon et al., 2012) and its analog imidazole ketone erastin (IKE) (Zhang et al., 2019), can block the GSH synthesis through inhibiting system $\chi_{C^{-}}$, and then reduce the GPX4 enzyme activity by GSH depletion; class II FIN such as Ras-selective lethal small molecule 3 (RLS3) (Yang and Stockwell, 2008), ML162 (Weißer et al., 2012), and ML210 (Eaton et al., 2020), can directly inhibit GPX4 activity. They eventually lead to the accumulation of lipid peroxides without the reduction of GSH (Yang et al., 2014). Apart from these two types of FINs, other methods or compounds can also induce ferroptosis (Figure 1): L-buthionine sulfoximine (BSO) suppresses glutamate-cysteine ligase (GCL) and induces GSH depletion (Seiler et al., 2008; Sun et al., 2018), driving cells to ferroptosis; Cystine starvation leads to glutamate accumulation, GSH biosynthesis reduction, and GPX4 translation blockage, therefore sensitizing cancer cells to ferroptosis (Zhang Y. et al., 2021). FINs and other compounds that cause ferroptosis drive tumor cell death, sensitizing cancer cells to radiotherapy and chemotherapy in prostate cancer (Li et al., 2021), colorectal cancer (Sui et al., 2018), osteosarcoma (Liu and Wang, 2019), and leukemia (Yu et al., 2015). Therefore, traditional chemotherapy/radiotherapy combined with FINs treatment is beneficial to reverse multidrug resistance.

POST-TRANSLATIONAL MODIFICATIONS OF GPX4 IN CANCER CELLS

Besides small molecular compounds like FINs, post-translational modifications (PTMs) also provide an emerging perspective to regulate its protein level/activity (Figure 2). Thus, studying and targeting PTMs of GPX4 has a great potential to treat cancers in the future.
Succination of GPX4
Succination was discovered in 2006 as a non-enzymatic, irreversible protein modification (Alderson et al., 2006). This post-translational modification is mediated by fumarate. Fumarate is an intermediate of the Krebs cycle in mitochondria. It binds to the sulphydryl group of the cysteine residue and forms a thioether bond in the absence of an enzyme (Blatnik et al., 2008; Manuel and Frizzell, 2013). An elegant study showed that intracellular fumarate aggregation led to the succination of GPX4 at cysteine 93 (mono- and di-succination), which significantly reduced the enzymatic activity of GPX4 and sensitized cancer cells to FINs (Kerins et al., 2018). In addition, fumarate hydratase (FH)-inactivated cells were shown to be synthetic lethal with FINs (Kerins et al., 2018). This study suggests that targeting PTMs of GPX4 is a promising therapeutic strategy for ferroptosis-related diseases for the first time.

Ubiquitination of GPX4
Ubiquitination is a reversible process in which the ubiquitin is added to lysine residue(s) of the substrate protein by three different types of enzymes, E1, E2, and E3. The process of ubiquitination ultimately renders proteins to degradation by the proteasome thereby affecting intracellular protein levels (Popovic et al., 2014). On the other hand, deubiquitinases (DUBs) remove ubiquitin chains from ubiquitinated proteins (Ronau et al., 2016). E3 ligase and DUB are both having substrate specificity.

Proteomic analyses reveal that GPX4 could be ubiquitinated at lysine 107, 162, and 167 (Wagner et al., 2011; Akimov et al., 2018). However, those hypothetically ubiquitinated residues have not been verified in bench works. Whereas, a study showed that when treating non-small cell lung cancer cells with the DUB inhibitor, pyridinium sulfur palladium complex (PdPT), GPX4 was ubiquitinated and degraded (Yang et al., 2020). Subsequently, cancer cell growth was restrained by inducing GPX4-dependent ferroptosis (Yang et al., 2020). Later, another study showed that a Parthenolide (PTL)-derived drug DMOCPTL directly bound to the GPX4 active site (selenocysteine 46), and led to GPX4 ubiquitination in triple-negative breast cancer cells (Ding et al., 2021). Unfortunately, the above-mentioned studies did not reveal the ubiquitinated residue(s) of GPX4.

Discovered the E3 ligase is also very important for understanding the regulatory mechanisms of protein ubiquitination. A very recent study discovered that the E3 motif-containing 46 (TRIM46) might be one of the E3 ligases of GPX4 in human retinal capillary endothelial cells with high glucose treatment (Zhang J. et al., 2021). Whether GPX4 has other E3 ligases is needed further investigation. These findings indicate that GPX4 can be ubiquitinated under certain circumstances. Importantly, treating cells with PdPT, DMOCPTL, or other similar compounds could potentially kill cancer cells by inducing ferroptosis.

Alkylation of GPX4
Alkylation is a chemical process of introducing one or more alkyl groups into a protein or a compound. An alkyl group is an alkane molecule that is missing a hydrogen atom. For example, methyl groups are the simplest alkyl and are added to various proteins including core histones (Chen et al., 1999; Strahl et al., 1999). Previous studies have shown several class II FINs such as RSL3 (Yang and Stockwell, 2008) and ML162 (Weïwer et al., 2012) exerted covalent inhibition activity. These class II FINs bound to selenocysteine 46 residue of GPX4 via an electrophilic alkyl chloride moiety, mediating alklyylation on GPX4 (Eaton et al., 2020; Vučković et al., 2020). Besides selenocysteine 46, GPX4 contains several cysteine residues which are also nucleophilic sites. A report showed that GPX4 was most likely alkylated at cysteine 107 with the addition of withaferin A (Grossman et al., 2017). In addition, the alklylation of GPX4 resulted in ferroptosis in high-risk neuroblastoma (Hassannia et al., 2017). However, Hassannia et al did not further investigate the specifically modified residue(s) of GPX4 or which kind(s) of alklylation occurs on GPX4.

POST-TRANSLATIONAL MODIFICATIONS OF GPX4 IN OTHER CONDITIONS
Phosphorylation of GPX4 is Involved in Sperm Maturation
Phosphorylation is one of the most common PTMs involved in the regulation of protein stability and activity. It occurs on serine, tyrosine, and threonine residues of target proteins and is regulated by protein kinases and phosphatases (Olsen et al., 2006). Phosphorylation of GPX4 has been found in the pig heart (Brigelius-Flohé et al., 1994), golden hamster’s sperms (Nagdas et al., 2005), and rat testicles (Lundby et al., 2012). Notably, the mature testicle is the organ with the highest GPX4 activity in mammals (Vernet et al., 2004), and sperm express high levels of GPX4 (Nam et al., 1998). Studies showed that GPX4 lost its enzyme activity during the differentiation and maturation of sperm (Ursini et al., 1999). Meanwhile, the phosphorylation of GPX4 on tyrosine has been found in capacitated sperm of the golden hamster (Nagdas et al., 2005). Several proteomic analyses also revealed that human GPX4 might be phosphorylated at serine 40 (Mertins et al., 2014; Mertins et al., 2016). These data indicate that phosphorylation of GPX4 participates in the GPX4 activity regulation. However, the exact phosphorylated residues, the corresponding phosphatases, and the biological effects of phosphorylation on GPX4 need to be further investigated.

N-Linked Glycosylation of GPX4 is Related to the Fertilization of Sperm
Glycosylation (N-linked and O-linked) is under the reaction of glycosyltransferases (Reilly et al., 2019). Protein glycosylation affects protein stability and folding (Molinari, 2007) and leads to changes in protein function. GPX4 has been identified as a membrane glycoprotein in an N-linked glycoproteome study in human sperm. The modification site was at the asparagine residue of GPX4 (Wang et al., 2013). In addition, deglycosylation treatment was also found to significantly decrease sperm fertilization rate (Wang et al., 2013). This study suggests that
SUMOylation of GPX4 Might Mediate Lipid Peroxidation Inhibition

In addition to phosphorylation and glycosylation, SUMOylation is also predicted to occur on GPX4. SUMOylation is a small ubiquitin-like modifier (SUMO) connected to the substrate protein through a tertiary enzymatic reaction (Tatham et al., 2001). It often modifies lysine residues of substrate proteins (Tatham et al., 2001). SUMOylation regulates the protein-protein interactions, mediates the function and localization of substrate proteins, and increases protein stability (Ouyang et al., 2009; Li et al., 2016; Han et al., 2018). A study using software resources (SUMOplot) for bioinformatics analysis predicted that the residues of GPX4 most likely to be modified by SUMO were lysine 74, 106, and 125 (Sheng et al., 2021). The cationic region of GPX4, including lysine 125, has the potential to interact with the phospholipid bilayer. Then the redox-active center of GPX4 was directed to the H2O2 group in the phospholipid fatty acid chain, resulting in the inhibition of lipid peroxidation of the cell membrane in silico (Cozza et al., 2017; Sheng et al., 2021).

Since GPX4 is a core regulator of ferroptosis, although it is unknown whether the phosphorylation, glycosylation or SUMOylation of GPX4 affect ferroptosis, it would be of interest to investigate it in future translational studies.

DISCUSSION AND FUTURE DIRECTION

PTMs are an important regulator of protein level and activity with huge potential in translational and clinical research. For instance, S-farnesylation is one of the post-translational protein lipid modifications (Nagase et al., 1997; Berndt et al., 2011). Hutchinson–Gilford progeria syndrome (HGPS) is a genetic rare disease caused by progerin formation due to a deficiency of removing a farnesylcysteine-containing peptide from prelamin A (Eriksson et al., 2003). Consequently, prelamin A turned into farnesylated and non-functional progerin instead of lamin A (Young et al., 2005). However, progerin was identified to be the critical target of farnesyltransferase inhibitors (FTIs) (Yang et al., 2010) and one FTI called lonafarnib have been tested in a cohort study which showed a significantly lower mortality rate (hazard ratio, 0.12) after a median of 2.2 years of follow-up (Gordon et al., 2018). S-palmitoylation is also an important PTM in many oncoproteins such as RAS-family GTPases (Dekker et al., 2010) and epidermal growth factor receptor (EGFR) and tumor suppressors such as melanocortin one receptor (MRC1) (Chen et al., 2017), which serves as an important target pathway to inhibit tumor growth and prevent tumorigenesis (Hernandez et al., 2017). Inducing palmitoylation in MCR1 variant individuals can lower their risk to develop melanoma (Chen et al., 2017). Targeting inhibition of palmitoylation has also shown sensitization to gefitinib in cancer cells (Bollu et al., 2015).

The investigation of the GPX4 function was far ahead of the emergence of ferroptosis. A variety of PTMs of GPX4 has been observed in both physiological and pathophysiological conditions. Targeting PTMs of GPX4 could be a promising strategy for treating diseases, including ferroptosis-related diseases such as cancers, neurodegenerative disorders, and ischemic-reperfusion diseases as well as other important players in ferroptosis (Wei et al., 2020). However, in contrast to other proteins, such as TP53 (Liu et al., 2019), studies on PTMs of GPX4 have only just started. At this point, we believe it is important to explore several aspects in future studies, such as to discover whether some of the PTMs summarized above affect GPX4 activity in bench works and GPX4 dysfunction-relative diseases. What are the corresponding enzymes of the above-mentioned PTMs? If other PTMs, such as methylation, lipoylation, or newly identified lactation also modify GPX4 protein? Since ferroptosis is an important cell death form in various conditions, and GPX4 is its core regulator, more in-depth studies are urgently needed to assist GPX4-based clinical therapeutic strategies for tumor killing and neuronal protection.

AUTHOR CONTRIBUTIONS

Writing-original draft: CC and QL. Writing-review and editing: CC, FY, and QL. All authors have agreed on the final version to be published.

FUNDING

This work was supported by the National Natural Science Foundation of China (32070735 to QL, 81971037 to FY), the Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ202010025033 to QL, KZ201910025026 to FY).

ACKNOWLEDGMENTS

We thank Wente Yi (Beijing University of Aeronautics and Astronautics) for his figure drafting assistance.

REFERENCES

Alderson, N. L., Wang, Y., Blatnik, M., Frizzell, N., Walla, M. D., Lyons, T. J., et al. (2006). S-(2-Succinyl)cysteine: a Novel Chemical Modification of Tissue Proteins by a Krebs Cycle Intermediate. Archives Biochem. Biophysics 450 (1), 1–8. doi:10.1016/j.abb.2006.03.005

Bannai, S. (1986). Exchange of Cystine and Glutamate across Plasma Membrane of Human Fibroblasts. J. Biol. Chem. 261 (5), 2256–2263. doi:10.1016/s0021-9258(17)35926-4
Berndt, N., Hamilton, A. D., and Sebti, S. M. (2011). Targeting Protein Prenylation for Cancer Therapy. *Nat. Rev. Cancer* 11 (11), 757–791. doi:10.1038/nrc3151

Blatnik, M., Thorpe, S. R., and Baynes, J. W. (2008). Succinylation of Proteins by Fumarate. *Annu. Rev. Biochem.* 77, 775–801. doi:10.1146/annurev.biochem.77.050807.164804

Bollu, L. R., Katreddy, R. R., Blessing, A. M., Pham, N., Zheng, R., Wu, X., et al. (2015). Intracellular Activation of EGFR by Fatty Acid Synthase Dependent Palmitoylation. *Oncotarget* 6 (35), 34992–35003. doi:10.18632/oncotarget.5252

Brigelius-Flohek, R., Aumann, K. D., Blocker, H., Gross, G., Kiess, M., Klöppel, D. E., et al. (1994). Phospholipid-hydroperoxide Glutathione Peroxidase. Genomic DNA, cDNA, and Deduced Amino Acid Sequence. *J. Biol. Chem.* 269 (10), 7342–7348.

Chen, D., Ma, H., Hong, H., Koh, S. S., Huang, S.-M., Hong, H., Koh, S. S., Huang, S.-M., Schurter, B. T., et al. (1999). Fumarate. *Eaton, J. K., Furst, L., Ruberto, R. A., Moosmayer, D., Hilpmann, A., Ryan, M. J., Dekker, F. J., Rocks, O., Vartak, N., Menninger, S., Hedberg, C., Balamurugan, R., Hassannia, B., Wiernicki, B., Ingold, I., Qu, F., Van Herck, S., Tyurina, Y. Y., et al. (2015). Intracellular Activation of EGFR by Fatty Acid Synthase Dependent Translation Modulation of Translational Replication Forks. *Int. J. Cancer* 137 (7), 1695–1700. doi:10.1002/ijc.29215

Ding, Y., Chen, X., Liu, C., Ge, W., Wang, Q., Hao, X., et al. (2021). Identification of a Small Molecule as Inducer of Ferroptosis and Apoptosis through Ubiquitination of GPX4 in Triple Negative Breast Cancer Cells. *J. Hematol. Oncol.* 14 (1), 19. doi:10.1186/s13045-020-01016-8

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: an Iron-dependent Form of Nonapoptotic Cell Death. *Cell* 149 (5), 1060–1072. doi:10.1016/j.cell.2012.03.042

Eaton, J. K., Furst, L., Ruberto, R. A., Moosmayer, D., Hilpmann, A., Ryan, M. J., et al. (2020). Selective Covalent Targeting of GPX4 Using Masked Nitrile-Oxide Electrophiles. *Nat. Chem. Biol.* 16 (5), 497–506. doi:10.1038/s41589-020-0501-5

Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., et al. (2017). Global, Site-specific, and Site-specific Phosphorylation Dynamics in the Powerful Guardian. *J. Mol. Biol. Cell* 11 (7), 564–577. doi:10.1093/jmbc/mjx060

Li, M., Chen, X., Wang, X., Wei, X., Wang, D., Liu, X., et al. (2021). RSL3 Enhances the Antitumor Effect of Cisplatin on Prostate Cancer Cells via Causes Glycophosphorylation Dysfunction. *Biochem. Pharmacol.* 192, 114741. doi:10.1016/j.bcp.2021.114741

Lui, S., Wang, M., Qu, X., Xu, Z., Yang, Y., Su, Q., et al. (2016). SUMOylation of PES1 Upregulates its Stability and Function via Inhibiting its Ubiquitination. *Oncotarget* 7 (31), 50522–50534. doi:10.18632/oncotarget.10494

Liu, Q., and Wang, K. (2019). The Induction of Ferroptosis by Impairing STAT3/Nfr2/GPX4 Signaling Enhances the Sensitivity of Osteosarcoma Cells to Ferroptosis. *Cell Biol. Int.* 43 (11), 1245–1256. doi:10.1002/cbin.11121

Manumycin and Gliotoxin derivative KT7595 Block Ras Farnesylation and Cell Growth but Do Not Disturb Lamin Farnesylation and Localization in Human Lung Cells. *Cell Biol. Int.* 2017 (7).doi:10.1002/cbin.11121

Molinar, M. (2007). N-glycan Structure Dictates Extension of Protein Folding or N-Glycosylation. *Proteomics* 7 (12), e1000252. doi:10.1002/pbc.1000252

Ngadis, S. K., Winfrey, V. P., and Olson, G. E. (2005). Tyrosine Phosphorylation and Treatment of Cancer. *Int. J. Oncol.* 298 (5), F1244. doi:10.3892/ijo.2006.320

Oncol. 6 (3), 313–320. doi:10.1038/nchembio880

Olsen, J. V., Blagoev, B., Gnädig, F., Macek, B., Kumar, C., Mortensen, P., et al. (2006). Global. In Vivo, and Site-specific Phosphorylation Dynamics in Signaling Networks. *Cell* 127 (3), 635–648. doi:10.1016/j.cell.2006.09.026

Petrukov, V. A., Gillette, M. A., Clauser, K. R., Mani, D. R., Petyuk, V. A., Gillette, M. A., et al. (2014). Proteogenomics Connects Somatic Mutations to Signalling in Breast Cancer. *Nature* 534 (7605), 55–62. doi:10.1038/nature18003

Ouyang, K. J., Woo, L. L., Zhu, J., Luo, D., Matusin, M. J., and Ellis, N. A. (2009). SUMO Modification Regulates BLM and RAD51 Interaction at Damaged Double-Stranded Breaks. *PLoS Biol.* 7 (12), e1000252. doi:10.1371/journal.pbio.1000252

Popovic, V., Vucic, D., and Dikic, I. (2014). Ubiquitination in Disease Pathogenesis and Treatment. *Nat. Rev. Mol. Cell Biol.* 15 (6), 346–366. doi:10.1038/nrm3739

Reilly, C., Stewart, T. J., Renfrow, M. B., and Novak, J. (2019). Glycosylation in Health and Disease. *Nat. Rev. Nephrol.* 15 (6), 734–750. doi:10.1038/s41581-019-0129-4

Synthetic Lethal with Ferroptosis Induction. *Cancer Sci.* 109 (9), 2757–2766. doi:10.1111/cas.13701

Futurology. *Biochem. Pharmacol.* 192, 114741. doi:10.1016/j.bcp.2021.114741

Suppressions of Proteins by Fumarate. *Annu. Rev. Biochem.* 77, 775–801. doi:10.1146/annurev.biochem.77.050807.164804

Preclinical Studies of Cancer Immunotherapy for Cancer Therapy. *Nat. Rev. Cancer* 11 (11), 757–791. doi:10.1038/nrc3151
Ronau, J. A., Beckmann, J. F., and Hochstrasser, M. (2016). Substrate Specificity of the Ubiquitin and Ubl Proteases. Cell Res. 26 (4), 441–456. doi:10.1038/cr.2016.38
Sato, H., Tamba, M., Ishii, T., and Bannai, S. (1999). Cloning and Expression of a Plasma Membrane Cystine/glutamate Exchange Transporter Composed of Two Distinct Proteins. J. Biol. Chem. 274 (17), 11455–11458. doi:10.1074/jbc.274.17.11455
Schuckelt, R., Brigelis-Flohe, R., Maiorino, M., Roveri, A., Reumkens, J., Strabburger, W., et al. (1991). Phospholipid Hydroperoxidase Glutathione Peroxidase Is a Seleno-Enzyme Distinct from the Classical Glutathione Peroxidase as Evident from Cdna and Amino Acid Sequencing. Free Radic. Res. Commun. 14 (5-6), 343–361. doi:10.1016/1079-5904(93)90342-4
Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., Culmsee, C., et al. (2008). Glutathione Peroxidase 4 Senses and Translates Oxidative Stress into 12/15-lipoxygenase Dependent- and AIF-Mediated Cell Death. Cell Metab. 8 (3), 237–248. doi:10.1016/j.cmet.2008.07.005
Sheng, Z., Zhu, J., Deng, Y.-n., Gao, S., and Liang, S. (2021). SUMOylation Active Nuclei in Tetrahymena. J. Proteome Res. 15 (10), 4182–4192. doi:10.1021/acs.jproteome.5b00791
Strahl, B. D., Ohba, R., Cook, R. G., and Allis, C. D. (1999). Methylation of Histone H3 at Lysine 4 Is Highly Conserved and Correlates with Transcriptionally Active Nuclei in Tetrahymena. Proc. Natl. Acad. Sci. U.S.A. 96 (26), 14967–14972. doi:10.1073/pnas.96.26.14967
Su, X., Zhang, R., Liu, S., Duan, T., Zhai, L., Zhang, M., et al. (2018). RSL3 Drives Ferroptosis through GPX4 Inactivation and ROS Production in Colorectal Cancer. Front. Pharmacol. 9, 1371. doi:10.3389/fphar.2018.01371
Sun, Y., Zheng, Y., Wang, C., and Liu, Y. (2018). Glutathione Depletion Induces Ferroptosis, Autophagy, and Premature Cell Senescence in Retinal Pigment Epithelial Cells. Cell Death Dis. 9 (7), 753. doi:10.1038/s41419-018-0794-4
Takege, G., Yarimizu, J., Saito, Y., Hayashi, T., Nakamura, H., Yodoi, J., et al. (2002). A Comparative Study on the Hydroperoxide and Thiol Specificity of the Glutathione Peroxidase Family and Selenoprotein P. J. Biol. Chem. 277 (43), 41254–41258. doi:10.1074/jbc.M202773200
Tatham, M. H., Jaffray, E., Vaughan, O. A., Desterro, J. M. P., Botting, C. H., Young, S. G., and Fong, L. G. (2010). Assessing the Effect of Protein Farnesytransferase Inhibitors in Mouse Models of Progeria. J. Lipid Res. 51 (2), 400–405. doi:10.1194/jlr.M002808
Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M. T., et al. (2015). The Ferroptosis Inducer Erastin Enhances Sensitivity of Acute Myeloid Leukemia Cells to Chemotherapeutic Agents. Mol. Cell. Oncol. 2 (4), e1054549. doi:10.1080/23723556.2015.1054549
Yang, S. H., Chang, S. Y., Andres, D. A., Spielmann, H. P., Young, S. G., and Fong, L. G. (2010). The Efficacy of Protein Farnesyltransferase Inhibitors in Mouse Models of Progeria: J. Lipid Res. 51 (2), 2531–2558. doi:10.1194/jlr.R500011-JLR200
Young, S. G., Fong, L. G., and Michaelis, S. (2005). Thematic Review Series: Lipid Posttranslational Modifications. Prelamin A, Zmpste24, Missshapen Cell Nuclei, and Progeria-New Evidence Suggesting that Protein Farnesylation Could Be Important for Disease Pathogenesis. J. Lipid Res. 46 (12), 2531–2558. doi:10.1194/jlr.R500011-JLR200
Zhang, J., Qiu, Q., Wang, H., Chen, C., and Luo, D. (2021a). TRIM46 Contributes to High Glucose-Induced Ferroptosis and Cell Growth Inhibition in Human Retinal Capillary Endothelial Cells by Facilitating GPX4 Ubiquitination. Exp. Cell Res. 407 (2), 112800. doi:10.1016/j.yexcr.2021.112800
Zhang, Y., Swanda, R. V., Nie, L., Liu, X., Wang, C., Lee, H., et al. (2021b). mTORC1 couples cys(e)ine availability with GPX4 protein synthesis and ferroptosis regulation. Nat. Commun. 12 (1), 1589. doi:10.1038/s41467-021-21841-w
Zhang, Y., Tan, H., Daniels, J. D., Zandkarim, F., Liu, H., Brown, L. M., et al. (2019). Imidazole Ketone Erastin Induces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem. Biol. 26 (5), 623–633. doi:10.1016/j.chembiol.2019.01.008

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cui, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.